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Abstract
Tissue injury and infection trigger innate immune responses. However, dysregulation may
result in chronic inflammation and is commonly treated with corticosteroids and non-steroi-
dal anti-inflammatory drugs. Unfortunately, long-term administration of both therapeutic
classes can cause unwanted side effects. To identify alternative immune-modulatory com-
pounds we have previously established a novel screening method using zebrafish larvae.
Using this method we here present results of an in vivo high-content drug-repurposing
screen, identifying 63 potent anti-inflammatory drugs that are in clinical use for other indica-
tions. Our approach reveals a novel pro-inflammatory role of nitric oxide. Nitric oxide affects
leukocyte recruitment upon peripheral sensory nervous system or epithelial injury in zebra-
fish larvae both via soluble guanylate cyclase and in a soluble guanylate cyclase -indepen-
dent manner through protein S-nitrosylation. Together, we show that our screening method
can help to identify novel immune-modulatory activities and provide new mechanistic
insights into the regulation of inflammatory processes.
Introduction
Inflammation is a highly regulated response of the innate immune system in reaction to tissue
injury or infection. However, its dysregulation may lead to chronic inflammatory states with
pathological consequences including autoimmune and neurodegenerative diseases [1]. Current
interventional therapies rely on corticosteroids and non-steroidal anti-inflammatory drugs
(NSAIDs) based on inhibiting the synthesis or action of inflammatory mediators. While corti-
costeroids induce general immune suppression, NSAIDs cause symptomatic relief by counter-
acting vasodilation, reducing fever and suppression of inflammatory pain [2]. However, long-
term administration of corticosteroids and NSAIDs often leads to unwanted side effects includ-
ing immunodeficiency, hyperglycemia or osteoporosis [3]. Thus, there is a demand for alterna-
tive therapeutics with higher specificity and less side effects [4].
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Drug repurposing, the testing of approved drugs for new off-label effects, promises to
accelerate the period from drug discovery to clinical use. In recent years the zebrafish
emerged as a particularly versatile vertebrate model organism for drug repositioning screens
[5]. Due to their small size and relative ease of manipulation and observation, zebrafish
embryos and larvae are perfectly suited for small molecule screens in a whole-animal context
[6]. In line with these notions, we recently developed a prototype automated high-content
screening approach in zebrafish that allows rapid phenotypic identification of immune-mod-
ulatory activities through chemical induction (ChIn) of tissue injury within the peripheral
sensory nervous system based on copper sulfate (CuSO4) treatment [7]. CuSO4 causes oxida-
tive stress in hair cells of lateral line neuromasts followed by hair cell death. This initiates an
acute inflammatory response, which is characterized by rapid recruitment of leukocytes to
injured neuromasts. Fluorescent reporter expression in both leukocytes and neuromasts
allows computer-aided automated signal detection and quantification of the inflammatory
response. Here we further refined this assay and report the results of an automated ChIn–
based screen of 1120 drugs identifying 63 potent anti-inflammatory hits from diverse phar-
macological classes, most of which were previously not associated with immune modulatory
activity.
Results and Discussion
An automated phenotypic screen for immune modulatory compounds in
zebrafish
We devised a fully automated screening strategy to screen small molecule libraries for immune
modulatory activities in zebrafish larvae (Fig 1A). The automated ChIn assay is a multi-
parametric assay capable of identifying not only compounds reducing (anti-inflammatory) or
exaggerating inflammation (pro-inflammatory), but also compounds affecting inflammation
resolution as well as providing information on compound toxicity and off-target effects.
We screened the FDA-approved drug library (640 compounds) and the ICCB library of
known bioactives (480 compounds) largely containing compounds in clinical use with well-
characterized bioactivity, bioavailability and biosafety properties. The compounds were gener-
ally screened at concentrations between 2 and 50 μM, with the exception of potent bioactive
lipids, which were screened at concentrations between 0.2 and 2 μM.
We created publically accessible webpages (https://www.iai.kit.edu/askme/ChIn/) visualiz-
ing all raw screening data including soft links to relevant heterogeneous biological and chemi-
cal databases, thus providing a valuable resource for further data analysis.
Based on phenotypic observations we determined three immune modulatory categories
(anti-resolution, pro- and anti-inflammatory) and empirically defined parameters for the
automated classification of screened compounds. A summary of the distinct immune modu-
latory classes and additional observed phenotypes are reported (S1–S5 Tables). To this end,
we generated a read-out, the inflammatory index, which is a measure for the degree of leuko-
cyte infiltration at injured neuromasts. Leukocyte numbers at injured neuromasts in controls
peaked at 90 min after initial copper treatment and inflammation resolved within 5 hours
(S1 Fig). To identify pro- and anti-inflammatory drugs we compared the initial inflammatory
index at peaking inflammation of each compound to that of the average CuSO4 control
(100%) (S1B and S1C Fig). Anti-inflammatory drug action was defined by an initial inflam-
matory index 50%. Pro-inflammatory drug action was defined by an initial inflammatory
index 150%. Anti-resolution drugs were characterized by inflammatory indices  50% at
5 h post-wounding, when inflammation was already resolved in controls. With these thresh-
olds 70 anti-inflammatory hits (6%) from diverse pharmacological classes were identified
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(Fig 1B, S1 Table). Seven compounds were NSAIDs, confirming the validity of our screening
approach, and 68 compounds (6%) were classified as pro-inflammatory (Fig 1B and S2
Table). At the tested concentrations 9 compounds (1%) prevented inflammation resolution
over time (Fig 1B and S1D Fig, S3 Table) and 48 drugs (4%) induced toxic or severe adverse
effects (Fig 1B and S1E Fig, S4 Table).
Hair cell viability after drug and copper treatment was assessed to identify injury-preventing
drugs (S1F Fig, S5 Table), which would otherwise be automatically falsely identified as anti-
inflammatory drugs. To this end, the nucleic acid stain Sytox Blue was used to reliably visualize
hair cell integrity (S2 Fig). Sytox Blue is sequestered specifically in intact hair cells. Once
nuclear fragmentation and hair cell extrusion from neuromasts occurs due to CuSO4-insult,
the fluorescent signal vanishes. This approach identified 38 (3%) injury-preventing drugs,
which were excluded from subsequent analysis (Fig 1B).
We further focused our analyses on the anti-inflammatory category. Grouping anti-inflam-
matory hits by function or therapeutic indication (Fig 2A) revealed that NSAIDs (n = 7; 10%),
antineoplastic agents and kinase inhibitors (n = 6; 9%), as well as antibiotics and calcium sig-
naling inhibitors (n = 5; 7%) were the most represented drug classes.
To validate the anti-inflammatory effect of selected candidates from the primary screen we
chose the following representatives of different drug classes (Fig 2B–2E): the proton pump
inhibitor Tenatoprazole, the adenosine receptor agonist NECA, the Angiotensin II Type I
receptor blocker Candesartan, and the nitric oxide synthase (NOS) 1 specific inhibitor
3-Bromo-7-nitroindazole. Dose-response analysis of these compounds revealed an increase in
anti-inflammatory drug action with increasing inhibitor concentrations for all tested drugs.
The anti-inflammatory effect of the NOS1 inhibitor suggests a pro-inflammatory role for NO
in a peripheral sensory nervous system injury model. We were thus interested to further evalu-
ate the role of NO in mediating inflammatory signals.
Fig 1. Experimental setup and compound categorization of the automated ChIn screen. (a) Schematic
diagram illustrating the screening strategy for compounds modulating inflammation. Individual larvae are
distributed in 384-well plates. Drugs are added 1 h prior to treatment with CuSO4 for 1h at 28°C in the dark
followed by an exchange of medium and a 6h time-lapse analysis. Finally, screening data are automatically
processed and analyzed. (b) Pie chart displaying the identified compound categories upon screening 1120
compounds of an FDA-approved library and the ICCB library of known bioactives. Numbers indicate
percentages.
doi:10.1371/journal.pone.0137286.g001
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NO is a pro-inflammatory signal in peripheral nervous system and
epithelial tissue injuries
To elucidate the universality of NO relevant for attraction of leukocytes to sites of wounding,
we studied the effect of different inhibitors of the NO signaling pathway in a peripheral nervous
system (ChIn) and an epithelial injury setting (Fig 3). Epithelial wounds were generated by
introducing an incision in the ventral fin fold and leukocyte influx to the site of wounding was
measured. In vertebrates three genetically distinct isoforms of NO synthase (NOS) have been
described [8]. The neuronal (nNOS, NOS1) and endothelial (eNOS, NOS3) isoforms are con-
stitutively expressed in multiple tissues and are regulated by calcium/calmodulin, while the
inducible NO synthase (iNOS, NOS2) can be transcriptionally induced especially in macro-
phages as a cytotoxic response mechanism [9]. Due to tissue-specific differences in the expres-
sion of distinct NOS isoforms, we tested two NOS inhibitors with differing isoform selectivity.
We used the pan-NOS inhibitor L-NAME in addition to our anti-inflammatory hit candidate
the NOS1 inhibitor 3-Bromo-7-Nitroindazole (3Br-7NI). To investigate the relevance of the
NO-sGC-cGMP axis, we further used an inhibitor (ODQ) for the soluble guanylate cyclase.
Similar to 3Br-7NI, the pan-NOS inhibitor L-NAME also produced a significant anti-inflam-
matory effect in the peripheral nervous system wound setting (Fig 3B). Moreover, both inhibi-
tors also resulted in a significant reduction of leukocyte infiltration in the epithelial wound
setting (Fig 3C). Therefore, NO is produced as a tissue-independent immediate pro-inflamma-
tory wound signal. Furthermore, inhibition of sGC with ODQ resulted in a significant anti-
inflammatory effect in both wounding scenarios implicating the NO-sGC-cGMP axis in leuko-
cyte-to-wound attraction.
Fig 2. Functional classification and validation of selected anti-inflammatory hits. Anti-inflammatory
candidates were classified in functional or therapeutic groups. Selected anti-inflammatory hit compounds
exert dose-dependent anti-inflammatory effect on chemically induced inflammation. (a) Pie chart dividing the
70 anti-inflammatory hit compounds in functional or therapeutic groups containing at least 2 representatives
(numbers). Groups with only one representative are summarized in “other”. (b—e) Dose-response behavior
of selected anti-inflammatory hit compounds Tenatoprazole (b), NECA (c), Candesartan (d), and 3-Bromo-
7-nitroindazole (e). Bar charts indicate means ± SEM of the initial inflammatory index (%) 90 minutes after
CuSO4 treatment (t = 0). Three individual experiments were performed with 15 replicate larvae for each
condition, respectively. Statistics were evaluated with unpaired one-sided t-tests. ns–not significant: P > 0.05,
* P < 0.05, ** P < 0.01, *** P < 0.001.
doi:10.1371/journal.pone.0137286.g002
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Nos2b mediates NO production in both inflammation scenarios
In order to identify the relevant zebrafish Nos isoform in inflammation, we applied genetic loss-
of-function by morpholino knockdown of zebrafish nos1 (nNOS), nos2a (iNOS) and nos2b as
well as gucy1a3 (sGC) to attenuate NO signaling (S3 Fig). The zebrafish genome includes one
nos1 and two nos2 genes but no distinct nos3 gene. Zebrafish nos2a expression is inducible in
vitro and in vivo by lipopolysaccharide [10]. Thus, the zebrafish Nos2a behaves as the mamma-
lian inducible NOS (iNOS) isoform. The nos2b gene is constitutively expressed during develop-
ment and in most adult zebrafish tissues. Along with an N-terminal myristoylation consensus
sequence, this suggests functional homology with mammalian NOS3 (eNOS) [10].
Anti-inflammatory activity of 3Br-7NI in both wounding scenarios suggested involvement
of zebrafish Nos1 in both peripheral sensory nervous system and epithelial inflammation.
Genetic knockdown experiments of all zebrafish nos isoforms however only confirmed a signif-
icant reduction of leukocyte-to-wound attraction upon knockdown of nos2b in both wounding
scenarios (Fig 4).
The soluble guanylate cyclase of mammals is an obligate heterodimer, consisting of one α
and one β subunit. Most tissues express a heterodimer of α1β1 [11]. To knockdown sGC activity
we therefore targeted the zebrafish α1 subunit (gucy1a3). A significant reduction of leukocyte
infiltration upon sGC knockdown was observed in both inflammatory settings (Fig 4).
Nitric oxide production results in protein S-nitrosylation during
inflammation
Alternatively, NO can exert effects by redox-based posttranslational protein modification (S-
nitrosylation). In order to investigate whether protein S-nitrosylation is a viable regulatory
Fig 3. Nitric oxide is a pro-inflammatory signal upon peripheral sensory nervous system and
epithelial tissue injuries. Inhibition of NOS and sGC significantly impairs leukocyte-to-wound attraction in
both inflammation scenarios. (a) Schematic of the NO signaling pathway. Relevant chemical inhibitors acting
on individual pathway components are indicated and color-coded. (b, c) Bar charts representing the effect of
the pan-NOS inhibitor L-NAME (magenta) (ChIn: 250 μM, ventral: 1000 μM), the NOS1 inhibitor 3-Bromo-
7-nitroindazole (blue) (3Br-7NI) (20 μM) and the sGC inhibitor ODQ (orange) (20 μM) on inflammation of the
peripheral sensory nervous system assessed by the ChIn assay (b) and on epithelial inflammation assessed
by mechanically induced injury of the ventral fin (c). Bar charts represent means of the inflammatory index
(%) ± SEM. Three individual experiments were performed with 15 replicate larvae for each condition,
respectively. Statistics were evaluated with unpaired one-sided t-tests. ns–not significant: P > 0.05, *
P < 0.05, ** P < 0.01, *** P < 0.001.
doi:10.1371/journal.pone.0137286.g003
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mechanism during inflammatory processes, we determined changes in total protein S-nitrosy-
lation during CuSO4 induced inflammation using the modified biotin-switch technique. We
observed differences in the degree of total protein S-nitrosylation between DMSO control and
CuSO4 treated groups (Fig 5). Total protein S-nitrosylation, marked by the appearance of addi-
tional strong anti-TMT immunoblotting signals significantly increased upon CuSO4 treatment.
Nos inhibition with 250 μM L-NAME prior to CuSO4 treatment prevented injury induced pro-
tein S-nitrosylation, suggesting a contribution of sGC-independent NO-mediated mechanisms
modulating the wound inflammatory response.
In recent years several phenotypic screens for modulators of behavior [12], modulators of
glucocorticoid signaling activity [13], hematopoietic stem cell formation [14], and others [15–
19] were successfully conducted in zebrafish. The translational relevance of drug discovery in
zebrafish is emphasized by the fact that several compounds identified in zebrafish screens were
successfully evaluated in preclinical trials [20,21] and even proceeded to phase 1b clinical trials
[5]. Whole organismal screens offer the unique advantage of studying interactions of com-
pounds with a physiological process of choice in its entire complexity. A multifaceted physio-
logical process such as the inflammatory response can be phenotypically assessed in zebrafish
in the presence of a fully functional innate immune system. The migration of leukocytes to
sites of injuries upon compound treatment allows detailed examination of the molecular play-
ers involved in surveillance of tissue homeostasis, sensation and mediation of inflammatory
signals as well as directed cell migration during an inflammatory response.
Thus far, three chemical-genetic screens have been conducted in zebrafish aiming at the
identification of immune modulatory compounds [22–24]. In these screens compounds were
manually assayed for the ability to suppress the recruitment of neutrophils to tail fin injuries.
In comparison, the ChIn assay–based screening approach applied here offers the unique
advantage of testing for immune-modulatory activities in vivo and in real time. Therefore, the
described setup allows assessment of compounds modulating inflammation initiation and res-
olution as well as revealing adverse and toxic drug effects. Importantly, chemical wounding
renders manual manipulation of larvae obsolete, thus permitting automation and screening in
a high-throughput format. To our knowledge, this study represents one of the first fully auto-
mated in vivo drug-repositioning screen performed in 384-well plate format [18,19]. One
drawback of chemically induced inflammation however is the possibility that compounds may
Fig 4. Genetic knockdown of zebrafish nos2b and sGC (gucy) but not nos1 and nos2a impair the
inflammatory response. Assessment of the role of the 3 zebrafish Nos isoforms and sGC on peripheral
sensory nervous system (a) and epithelial (b) inflammation upon genetic knockdown. (a) nos2b and gucy
knockdown significantly reduce initial inflammation at injured neuromasts as compared to wildtype (WT)
larvae. (b) Knockdown of nos2b and gucy significantly reduce the number of neutrophils recruited to ventral
fin wounds. Bar charts represent means of the initial inflammatory index (%) ± SEM 90 minutes after CuSO4
treatment (a) and 1 h after mechanical injury of the ventral fin (b). Three individual experiments were
performed with 15 replicate morphant larvae for each condition, respectively. Statistics were evaluated with
unpaired one-sided t-tests. ns–not significant: P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001.
doi:10.1371/journal.pone.0137286.g004
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interfere with the hair cell damaging agent CuSO4, thereby preventing neuromast damage. We
therefore identified injury-preventing drugs through assessment of hair cell viability after drug
and copper treatment and found 38 compounds (3%) in this category. The mode of action
underlying the hair cell protective effect was not further investigated. It is likely that many of
the injury preventing drugs have chemical properties capable of chelating Cu2+-atoms through
the formation of two or more coordinate bonds, thereby attenuating the detrimental CuSO4
effects. Similarly, general otoprotective effects may also reduce the cell damaging activity of
CuSO4. However, the relatively minor proportion of drugs preventing hair cell damage upon
CuSO4 treatment can be probed for true immune modulatory activity in a low-throughput
copper-independent mechanical wounding assay.
We here focused on the anti-inflammatory category of compound hits and defined anti-
inflammatory drug activity by a significant reduction in neutrophil numbers at damaged neu-
romasts in analogy to the IC50 value. This threshold resulted in 70 anti-inflammatory modula-
tors representing 6% of the screened drugs. The 70 compounds represent 13 different drug
classes according to function or therapeutic indication with two or more compound hits. In
addition, 22 of these compounds represent individual therapeutic or functional classes. The
Fig 5. Inflammation induces S-nitrosylation in zebrafish larvae.Changes in total protein S-nitrosylation
during inflammation was assessed with the modified biotin switch technique and detected byWestern Blot. S-
nitrosylated proteins in samples of control (lane 1) larvae and larvae with chemically induced inflammation
(lane 2 and 3) were detected by anti-TMT immunoblotting. Chemically induced inflammation significantly
induces S-nitrosylation, marked by additional strong anti-TMT immunoblotting signals (arrowheads), in
protein extracts of CuSO4 treated larvae. Inhibition of Nos with 250 μM L-NAME prior to CuSO4 treatment
prevents changes in protein S-nitrosylation. EF–1α was used as loading control.
doi:10.1371/journal.pone.0137286.g005
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largest pharmacological group within the anti-inflammatory category are NSAIDs, confirming
the validity of our screening approach. At the chosen screening concentration and threshold
for anti-inflammatory drug activity, 19% of all NSAIDs within the screened libraries were
detected. This observation confirms that NSAIDs are generally not very potent anti-inflamma-
tories. Other pharmacological classes, each containing 5 or more representatives with anti-
inflammatory properties are antineoplastic agents and kinase inhibitors (n = 6; 9%). 7% of all
hits (n = 5) were inhibitors of calcium signaling and antibiotics, respectively. Calcium is one of
the most immediate messengers upon mechanical and laser induced wounding in neuronal
and epithelial tissues initiating the wound inflammatory response in different model organisms
[25–27]. In these studies, initial wound-derived calcium signaling from extra- and intracellular
stores proved indispensible for immune cell recruitment to sites of injuries and for subsequent
regenerative responses. We identified different calcium channel inhibitors specific for inhibi-
tion of calcium influx or release from both extra- and intracellular sources to significantly sup-
press leukocyte-to-wound attraction. These results suggest a critical role of calcium from both
extra- and intracellular sources also for efficient mounting of the wound inflammatory
response in our chemically induced peripheral sensory nervous system injury model.
For hit validation we positively validated representatives of four compound classes in dose-
response-behavior analysis using the chemically induced inflammation assay.
Angiotensin II Type 1 receptor blockers (ARBs) such as Candesartan are reportedly effective
in hypertension related vascular inflammation in peripheral organs. Our observations with
Candesartan confirm the hypothesized immune modulatory activity of ARBs beyond hyper-
tension [28].
Proton pump inhibitors (PPIs) such as Tenatoprazole are used in the treatment of gastro-
oesophageal reflux disease to inhibit the H+/K+ ATPase of gastric parietal cells. Recently, a
number of mechanisms were discussed based on in vitro data, whereby PPIs may exert anti-
inflammatory effects unrelated to the inhibition of gastric acid production [29]. In accordance,
we here report an in vivo inhibitory effect of PPIs on leukocyte recruitment to sites of periph-
eral nervous system injuries.
NECA is a selective agonist of adenosine A2A receptors expressed on leukocytes [30]. Sig-
naling via A2A receptors suppresses inflammatory and immune responses by reducing the pro-
duction of many pro-inflammatory cytokines and inhibition of adhesion molecule expression
[31].
3-Bromo-7-nitroindazole is described as a NOS1 inhibitor. Measurements in experimental
animal models with spinal cord injuries revealed that NO accumulates and nitric oxide
synthase (NOS1) activity increases in injured tissues [32]. In addition, a distinct temporal pat-
tern of nitric oxide production with modulation of NO concentrations marked by an immedi-
ate increase, a decrease between 1 and 12 h after injury and a second wave of NO production
between 24 h and 3 days after injury was described. The later wave of NO production is attrib-
uted to inducible nitric oxide synthase (NOS2) expression in damaged tissues starting approxi-
mately 2 h after injury and steadily increasing thereafter [32]. Despite the well documented NO
accumulation in injured tissues, the actual role of NO upon tissue injury is controversially dis-
cussed. Some reports argue for a protective, others for a detrimental role of NO with respect to
neurotoxic and neuroprotective effects after traumatic tissue injury.
Although the function of NO upon neuronal injuries is certainly complex, our in vivo data
suggest that NOmodulates leukocyte attraction to peripheral sensory nervous system injuries
indicating that modulation of NO signaling might be therapeutically beneficial for patients
with acute and chronic inflammatory conditions. Dibaj et al. reported a role for NO in the
recruitment of microglia to lesions of spinal cord white matter in mice [33]. Superfusion with
NOS inhibitors prior to spinal cord white matter tissue damage inhibited microglial extensions
A Zebrafish Drug-Repurposing Screen and Nitric Oxide
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towards the lesion. Taken together with the results presented here, these studies indicate that
NO attracts leukocytes specifically to neuronal and peripheral nervous system injuries. Our
observation that inhibition of Nos also reduced neutrophil recruitment to mechanically
inflicted epithelial wounds in the zebrafish ventral fin extends the role of NO to a conserved
pro-inflammatory one in both neuronal and epithelial injury settings.
Pharmacological inhibition of sGC, the only known receptor for NO, significantly reduced
attraction of leukocytes to sites of peripheral sensory nervous system and epithelial injuries. It
is therefore conceivable that sGC may act as a receptor on leukocytes, perceiving directional
cues from NO, regulating chemotaxis of leukocytes. This notion is also in line with findings by
Duan and Dibaj et al. who reported that sGC inhibition affected directional movement of
microglia, resulting in reduced microglia accumulation at leech nerve cord lesions and spinal
cord white matter injuries in mice [33,34]. Our data suggest that NO may also contribute to
the inflammatory response in an sGC-independent manner via protein S-nitrosylation. sGC-
mediated NO effects may primarily target immune cells, while S-nitrosylation governs NO
responses in cells at and around the site of injury affecting the production of secondary pro-
inflammatory mediators. For example, S-nitrosylation activates cytosolic phospholipase A2α,
which is the rate-limiting key enzyme cleaving arachidonic acid from membrane phospholipids
for eicosanoid production including prostaglandin E2 [35]. Furthermore, S-nitrosylation acti-
vates cyclooxygenase–2 and enhances its catalytic activity. Consequently, sGC-independent
NO action results in the production of pro-inflammatory lipid mediators. Other known NO-
regulated targets are matrix metalloproteinases, most importantly MMP–9, which are involved
in remodeling of extracellular matrix [36]. MMP–9 activation by protein S-nitrosylation may
thus facilitate leukocyte tissue transmigration.
There is ample evidence of an intricate interplay between NO and calcium signaling. NO pro-
duction by constitutive nitric oxide synthases (NOS1 and NOS3) is regulated by intracellular cal-
cium concentrations [8]. Simultaneously, NO is implicated in affecting calcium signaling. For
instance, NO was suggested as a paracrine messenger promoting intracellular calcium wave propa-
gation [37]. Additionally, NO has implications in regulating extra- and intracellular calcium flux
through protein S-nitrosylation via TRP channels [38] and IP3 receptors [39], respectively. Accord-
ingly, we found several calcium channel inhibitors including the IP3 receptor inhibitor 2-APB and
the TRP channel modulator 6-gingerol with significant anti-inflammatory properties. NOmay
thus act as a feed-forward signal to promote and/or sustain injury-induced calcium signaling. It
will be intriguing to decipher actual targets of S-nitrosylation in an inflammatory context.
Through genetic inhibition we identified the relevant zebrafish Nos isoform critical for effi-
cient mounting of an inflammatory response. Genetic inhibition of all Nos isoforms revealed
that only zebrafish nos2b significantly reduced leukocyte-to-wound attraction. Interestingly,
heterocyclic compounds such as 7-Nitroindazole (7-NI) were reported to have greater selectiv-
ity towards NOS1 in vivo, while exhibiting equipotent efficiency for all NOS isoforms when
examined against isolated enzyme preparations [40]. While our pharmacological data using
the 7-NI derivative 3Br-7NI would therefore suggest zebrafish Nos1 as the relevant isoform,
the genetic data clearly identifies zebrafish Nos2b in the described inflammatory context. Thus
3Br-7NI efficiently inhibits Nos2b in an in vivo zebrafish inflammation model.
This work described here employs a fully automated in vivo phenotypic screening approach
in zebrafish larvae providing a comprehensive data set for systematic immune modulatory
drug discovery in the context of an intact innate immune system. Further investigation of nitric
oxide signaling upon the anti-inflammatory activity of a nitric oxide synthase inhibitor sub-
stantiates the role of NO as an important tissue-independent pro-inflammatory mediator criti-
cal for the attraction of leukocytes to wounds. Further, this study provides new mechanistic
insights into nitric oxide mediated regulation of inflammatory processes.
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Methods
Aquaculture and transgenic fish lines
Zebrafish husbandry and experimental procedures were performed in accordance with the
German animal protection standards and were approved by the Regierungspräsidium Karls-
ruhe, Germany (General license for fish maintenance and breeding: Az.: 35–9185.64). All
embryos were collected by natural spawning, and raised at 28°C in E3 medium (see S6 Table
for transgenic lines used). All animals subjected to experimentation were anesthetized in MS–
222 (Sigma-Aldrich A5040).
Chemical Libraries and pharmacological perturbations
The FDA-approved drug library (BML–2841 v.1.4) and the ICCB library of known bioactives
(BML–2840 v.2.1) (Enzo Life Sciences) were screened at concentrations ranging from 0.2–
50 μM. Anti-inflammatory candidate compounds were purchased at Santa Cruz Biotechnology
and tested at drug concentrations ranging from 1–20 μM. Drugs affecting NO signaling such as
3-Bromo-7-nitroindazole (NOS1), 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ)
(sGC), and Nω-Nitro-L-arginine methyl ester (L-NAME) hydrochloride (pan-NOS) were used
at concentrations ranging from 10–50 μM and 250–1000 μM, respectively.
Automated chemically induced inflammation assay (ChIna)
The ChIna assay was performed as previously described [7]. Images were acquired on an
inverted automated Olympus Scan⌃R microscope 90 minutes after initial copper treatment.
Each well was imaged once per hour for six hours in the channels brightfield, Cy3 and GFP in
4 focal planes (50 μm distance) using a 4x objective (N.A. = 0.13).
Quantification of inflammation
Image processing and quantification of inflammation was accomplished with custom devel-
oped software scripts based on LabView and MATLAB [7]. In brief, extended focus RGB over-
lay images from the channels GFP, brightfield and Cy3 were generated. Green fluorescent
neuromasts were detected using a pattern recognition tool. As primary read-out we scoring the
percent area occupied by leukocytes (Paol) in an empirically defined area of interest around
injured neuromasts.
Screening statistics
Each 384-well plate contained 320 compounds and 32 positive (CuSO4) and negative controls
(DMSO), respectively. The Paol of the 32 control replicates was averaged and standard devia-
tion was calculated. Only data points within 2 standard deviations were included. The average
Paol of DMSO was set to 0 and the averaged Paol for the CuSO4 was set to 1. After normaliza-
tion each compound’s Paol was linearly interpolated or extrapolated to the respective controls
on the experimental plate. Normalized raw data from 15 replicate experiments were averaged,
resulting in the inflammatory index. A monotonic exponential nonlinear regression fitting
towards the initial inflammation was performed eða0þa1tÞ. A0 is a measure for the initial response
at t = 0, a1 is related to the slope of magnitude over time. The initial inflammatory index (%)
displayed in bar charts was obtained by solving the nonlinear regression (eða0þa1tÞ) for t = 0.
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Immune modulatory categories
Anti-inflammatory drug action was defined by an inflammatory index 50% (a0  -0.68) 90
minutes after initial copper treatment (t = 0). The threshold for pro-inflammatory drugs was
set to an inflammatory index 150% (a0  0.41) at t = 0. The threshold parameters for anti-
resolution drugs were a0  -0.21 (inflammatory index 80% at t = 0) and a1  -0.12. Com-
pounds were considered as “normal” with the following parameters: -0.68< a0 < 0.41 and a1
< -0.12.
Screening results
All screening data is accessible at https://www.iai.kit.edu/askme/ChIn/
Manual chemically induced inflammation assay (ChInm)
The manual ChIn assay was performed with morphant larvae. The manual ChIn assay was car-
ried out analogous to the automated ChIn assay, with minor variations. All treatments were
performed in 6-well plates in a volume of 3 ml. The inflammatory response was quantified by
manual counting of leukocytes within the horizontal myoseptum [41]. The inflammatory
index was obtained by normalization of experimental conditions to the average cell count of
the CuSO4 control.
Ventral fin assay
Epithelial inflammation was assessed in ventral fins of Tg(lyz:DsRED2)nz50 larvae upon nick-
ing the ventral fin fold of anesthetized larvae with a sterile scalpel. Larvae were left to recover
for 1 h in presence or absence of drug prior to microscopic analysis. Fluorescent leukocytes
were counted in an area of interest around the wound. The inflammatory index was obtained
by normalization of experimental conditions to the average cell count of the positive control.
Identification of compounds preventing CuSO4 induced neuromast
damage
Hair cell damage was assessed using the nuclear acid stain Sytox Blue (Molecular Probes
S34857). Larvae were incubated for 2 h in E3 supplemented with DMSO (1%) and Sytox Blue
(5 μM final concentration) and washed two times with E3 containing 1% DMSO and MS–222
prior to the automated ChIn assay procedure. Brightfield and DAPI images were acquired 90
minutes after initial CuSO4 treatment to assess hair cell integrity.
Morpholino knockdown
Morpholino oligonucleotides were obtained from Gene Tools and injected at non-toxic con-
centrations (MOnos1: 0.08 mM, MOnos2a: 0.4 mM, MOnos2b: 0.2 mM, MOgucy1a3: 0.15
mM) into one-cell stage zebrafish embryos. Gene knockdown was confirmed by RT-PCR (S3
Fig; S6 Table).
Detection of S-nitrosylation
S-nitrosylation was analyzed in larval extracts using the S-nitrosylation Western Blot kit
(Thermo Scientific 90105) according to the manufacturer’s protocol with minor variations
mentioned below. Larvae were treated with L-NAME (250 μM) or DMSO (1%) for 1 h, fol-
lowed by 10 μMCuSO4 treatment for 45 min at 28°C in the dark and washed 3 times with PBS
supplemented with MS–222. Proteins were extracted in HENS buffer. 60 μg of protein was
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used per labeling reaction. MMTS was used at 200 μM and blocking was performed at 50°C
with constant shaking and 10 μg of protein was loaded per lane.
Statistical Analysis
Statistical analyses were performed using Prism 5.0 (GraphPad). Drug effects were assessed by
comparing inflammatory indices of drug versus control using unpaired, one-tailed t-tests. All
data presented in bar charts show means ± SEM.
Supporting Information
S1 Fig. Inflammatory kinetics of the major immune modulatory categories, injury prevent-
ing compounds and toxic compounds. Kinetics of the inflammatory response of 1120 com-
pounds from the FDA- approved library and the ICCB library of known bioactives. Individual
graphs display the inflammatory index over time based on non-linear regression fitting of orig-
inal data using eða0þa1tÞ for the different categories. Red dots in each graph represent the inflam-
matory index of the averaged CuSO4 control. Black curves represent individual compounds.
(a) Compounds with normal inflammatory response. (b) Drugs with anti-inflammatory activ-
ity. (c) Pro- inflammatory compounds. (d) Anti-resolution compounds. (e) Toxic compounds
and compounds with severe adverse effects. (f) Injury preventing compounds. The majority of
compounds in this category mimic anti- inflammatory drug activity.
(PDF)
S2 Fig. Identification of injury preventing compounds with Sytox Blue. Images show 3 dpf
wildtype larvae stained with Sytox Blue (a) DMSO control. Sytox Blue is sequestered to intact
hair cells (indicated with white arrowheads). (b) CuSO4 control. Sytox Blue fluorescence van-
ishes upon nuclear fragmentation due to CuSO4 treatment. (c) Exemplary injury preventing
compound. Intact hair cells are marked with white arrowheads.
(PDF)
S3 Fig. Morpholino knockdown of three zebrafish nos isoforms and gucy1a3. Knockdown
efficacy was assessed by semi-quantitative measurements of altered or reduced transcript levels
via RT-PCR. RT-PCR was performed on batches of 15 pooled splice site morpholino (MO)
injected (+) and control (-) larvae, respectively. Injection of MOnos1 (0.08 mM) splice site MO
results in an additional shorter PCR product. Injection of MOnos2a (0.4 mM) significantly
reduces nos2a transcript levels. Successful knockdown of nos2b by injection of the splice block-
ing MO (0.2 mM) is evident by generation of alternate PCR products. Efficient knockdown of
gucy1a3 in (0.15 mM) MO injected larvae results in generation of transcripts shorter or longer
than wildtype, respectively.
(PDF)
S1 Table. (Related to Fig 1) Anti-inflammatory compounds.
(PDF)
S2 Table. (Related to Fig 1) Pro-inflammatory compounds.
(PDF)
S3 Table. (Related to Fig 1) Anti-resolution compounds.
(PDF)
S4 Table. (Related to Fig 1) Toxic compounds and compounds with adverse effects.
(PDF)
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S5 Table. (Related to Fig 1) Injury preventing compounds.
(PDF)
S6 Table. Transgenic zebrafish lines, oligonucleotide and morpholino sequences.
(PDF)
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